

# Isolation and Characterization of Urine Microvesicles from Prostate Cancer Patients: Different Approaches, Different Visions

**María García-Flores**

Fundación Instituto Valenciano de Oncología

**Christian M. Sánchez-López**

University of Valencia

**Marta Ramírez-Calvo**

Fundación Instituto Valenciano de Oncología

**Antonio Fernández-Serra**

Fundación Instituto Valenciano de Oncología

**Antonio Marcilla**

University of Valencia

**José Antonio López-Guerrero** (✉ [jalopez@fivo.org](mailto:jalopez@fivo.org))

Fundación Instituto Valenciano de Oncología

---

## Research Article

**Keywords:** Extracellular microvesicles, Exosomes, Ultracentrifugation, Size exclusion chromatography, miRNA

**DOI:** <https://doi.org/10.21203/rs.3.rs-183251/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

Because of their specific and biologically relevant cargo, urine extracellular vesicles (EVs) constitute a valuable source of potential non-invasive biomarkers that could support the clinical decision-making to improve the management of prostate cancer (PCa) patients. Different EV isolation methods differ in terms of complexity and yield, conditioning, as consequence, the analytical result.

## Methods

The aim of this study was to compare three different isolation methods for urine EVs: ultracentrifugation (UC), size exclusion chromatography (SEC), and a commercial kit (Exolute® Urine Kit). Urine samples were collected from 6 PCa patients and 4 healthy donors (HDs). After filtered through 0.22 µm filters, urine was divided in 3 equal volumes to perform EVs isolation with each of the three approaches. Isolated EVs were characterized by spectrophotometric protein quantification, nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), AlphaScreen Technology, and whole miRNA Transcriptome.

## Results

Our results showed that UC and SEC provided better results in terms of EVs yield and purity than Exolute®, non-significant differences were observed in terms of EV-size. Interestingly, luminescent AlphaScreen assay demonstrated a significant enrichment of CD9 and CD63 positive microvesicles in SEC and UC methods compared with Exolute®. This heterogeneity was also demonstrated in terms of miRNA content indicating that the best correlation was observed between UC and SEC.

## Conclusions

Our study highlights the importance of standardizing the urine EV isolation methods to guaranty the analytical reproducibility necessary for their implementation in a clinical setting.

## Background

The diagnosis of prostate cancer (PCa) is currently made by histological confirmation from a biopsy obtained as a result of altered serum prostate-specific antigen (PSA) values ( $\geq 4$  ng / ml) and/or a suspicious digital rectal examination (DRE) [1–3]. However, this approach presents many limitations including low specificity of PSA and DRE and the molecular heterogeneity of PCa that determines the progression of the tumor [4]. For this reason, there is an urgent need in developing more targeted and non-invasive diagnostic tools, based on the molecular characterization of body fluids, that provide information about the malignant potential of PCa and that allow the monitoring of the disease into the different treatment scenarios.

Urine, due to the anatomic proximity of the prostate gland to the urethra, constitutes a valuable source of PCa biomarkers particularly derived from exfoliated prostatic cells, excreted proteins, circulating nucleic acids or extracellular vesicles (EVs) after a slight prostate massage [5]. EVs are small membrane vesicles that are classified according to their size, cellular origin and biogenesis into microvesicles, exosomes, and apoptotic bodies [6, 7]. They are released by most cell types in physiological and pathological conditions [7] and can be isolated from all body fluids (including urine, blood, saliva, milk, semen, cerebrospinal fluid, etc.) [8, 9]. EVs contains a variety of molecules including nucleic acids, proteins, lipids and some other metabolites [10–12], and their composition is affected by different environmental factors and health status [13, 14]. Given their ability to horizontally transfer genetic material and signaling moieties between different cells in the organism, EVs have recently emerged as powerful mediators of cell-cell communication [7].

Currently, EVs-cargo represents a doubtless source of biomarkers that may represent the different PCa stages of progression [15, 16] and constitute promising tools for the development of minimally invasive diagnostic procedures. Hence, because of their increasing potential for their use in clinical situations, it has become vitally important to improve the isolation method for maximum purity, yield, and assay reproducibility [17]. The most common approaches to isolate EVs from body fluids, are: size exclusion chromatography (SEC); classical ultracentrifugation (UC) [17]; sucrose density-gradient centrifugation; affinity chromatography using antibodies against EVs markers (such as CD9, CD81, CD63) [18]; or commercial kits [8, 19–21]. Despite their importance, EVs isolation and characterization are still considered major scientific challenges [22, 23], and identifying the best techniques to isolate exosomes is crucial for further biomarker discoveries.

The aim of this study was to compare three different EVs isolation methods: UC, SEC, and a commercial kit (Exolute® Urine Kit) using urine from a series of PCa patients and healthy donors (HDs). The outperformance of the three methods was evaluated by using different analytic approaches, including NanoDrop protein quantification, nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), AlphaScreen Technology, and HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA).

## Methods

### Sample collection and ethical considerations

Urine samples from PCa patients (6 men) and HDs (4 men, with no history of cancer or other prior chronic diseases), were retrieved from the archives of the Biobank of the Fundación Instituto Valenciano de Oncología (FIVO). Written informed consent for sample donation for research purposes was obtained from all patients prior to sample collection, and the study was approved by the Clinical Research Ethics Committee (CREC) and the Institutional Ethics Committee (Ref. PROMETEO 2016/103), at the meeting held on May 28, 2015. All methods used during the study were performed in accordance with the relevant guidelines and regulations.

### Urine processing

A median of 72mL (range: 54-90mL) of urine were collected in sterile urine containers (Ref. 409726 Deltalab, Barcelona, Spain). Protease Inhibitor Cocktail (P8340-5mL, Sigma Aldrich, San Luis, MO, USA) was added to preserve exosomes (50 µL cocktail in 100mL urine sample) [54]. Each sample was centrifuged at 1,000 x g, 10 min at 4°C, and supernatant were frozen at -80°C until use. The pre-analytical variables of the samples with SPREC code [51, 55, 56] are shown in Table 1.

Table 1

Preanalytical variables included in the Standard PREanalytical Code (SPREC), applied to urine samples

Sample ID	Type of sample	SPREC code*
127	PCa patient	URN-PIX-D-D-N-N-J
129	PCa patient	URN-PIX-D-D-N-N-J
132	PCa patient	URN-PIX-A-D-N-N-J
144	PCa patient	URN-PIX-B-D-N-N-J
146	PCa patient	URN-PIX-B-D-N-N-J
148	PCa patient	URN-PIX-B-D-N-N-J
161	HDs	URN-PIX-A-D-N-N-J
163	HDs	URN-PIX-A-D-N-N-J
164	HDs	URN-PIX-A-D-N-N-J
167	HDs	URN-PIX-A-D-N-N-J

\*Each biospecimen is assigned a seven-element-long code that corresponds to seven preanalytical variables. First code element: type of sample (URN: urine). Second code element: type of primary container (PIX: with Protease inhibitors). Third code element: precentrifugation (A: RT < 2 h, B: 3°C to 7°C < 2 h, D: 3°C to 7°C 2–4 h). Fourth code element: centrifugation (D: 3°C to 7°C 10 min < 3,000 g with braking). Fifth code element: second centrifugation (N: No centrifugation). Sixth code element: postcentrifugation (N: Not applicable). Seventh code element: storage condition [J: PP (Poly propylene) tube ≥ 5mL (-85) to (-60) °C. If the preanalytical option used is unknown or inconstant, the letter "X" is used. If the preanalytical option used is known but does not correspond to any of the standard options, the letter "Z" is used. (RT: room temperature 18°C to 25°C) [58].

Urine samples were thawed at 4°C before use. Samples were centrifuged at 1,000 x g, 15 min at room temperature (RT) to remove cell debris, and the collected supernatants were then centrifuged at 3,000 x g, 15 min at 4°C. The major urinary contaminant, mucoprotein (the Tamm-Horsfall protein), was removed by adding NaCl to a final concentration of 0.58 M and incubated for 2h at RT, as previously described [57]. Samples were then centrifuged at 16,000 x g, for 20 min at 4°C, and the supernatant was collected and filtered through 0.22 µm membrane filters (Thermo Fisher Scientific, Waltham, MA, USA). Finally, the total volume of urine from each sample was divided into 3 equal parts, to perform the 3 different EVs isolation methods.

## Isolation methods

## **ExoLutE® Urine Kit.**

Urine supernatants were concentrated to a final volume of 7 mL using Amicon® Ultra-4 Centrifugal Filter Devices (EMD Millipore Burlington, Ma, USA), and then processed with ExoLutE® Urine Kit (Rosetta Exosome® Inc., Seoul, Republic of Korea) following the manufacturer's instructions. A total of 130 µL of EVs-enriched samples were obtained.

## **EVs enrichment by ultracentrifugation (UC).**

Urine supernatants were centrifuged at 100,000 x g, 2h at 4°C (in a 50.2 Ti Titanium rotor, Beckman coulter, using a CP100NX ultracentrifuge, Hitachi). The 100,000 x g pellet was resuspended in 150 µL of filtered Phosphate-Buffered Saline (PBS).

## **Size Exclusion Chromatography (SEC).**

EVs isolation was performed as described by Böing *et al* [59]. Briefly, up to 12 mL of Sepharose-CL2B (Sigma-Aldrich, San Luis, MO, USA) were stacked in a 15 mL syringe (Sigma-Aldrich, San Luis, MO, USA), and washed 3 times with PBS, previously filtered through 0.22 µm membrane filters, and also used as elution buffer. Samples were concentrated using Amicon® Ultra-4 Centrifugal Filter Devices (EMD Millipore, Burlington, MA, USA) by centrifugation at 3,200 x g, 20 min at 4°C. Then, up to 0.75 mL of concentrated urine was loaded into the column, and a total of 20 fractions of 0.5 mL were collected from each sample. Fractions 8 and 9 were pooled and selected for further EVs analysis.

## **Characterization methods**

### **NanoDrop quantification.**

The protein concentration in each sample was measured at 280 nm absorbance using a NanoDrop 1,000 spectrophotometer (Thermo Scientific, Waltham, MA, USA).

### **Nanoparticle tracking analysis (NTA).**

Size distribution of particles was determined by NTA in a NanoSight LM10 (Malvern Instrument Ltd, Malvern, UK), using a 405 nm laser and sCMOS camera. Data were analyzed with using the NTA software version 3.3 (Dev Build 3.3.104), with Min track Length, Max Jump Distance, and Blur set to auto, and detection threshold set to 5. Camera level was set to 15, and 5 readings of 30 s at 30 frames per second were taken with manual monitoring of temperature. Samples were diluted with filtered PBS to reach the concentration (20–120 particles/frame) recommended by the manufacturer.

## Transmission Electron Microscopy (TEM).

Sample preparation was performed as already described [60] with modifications. Briefly, 8  $\mu\text{L}$  of EVs-containing samples were fixed in 2% paraformaldehyde (PFA) for 30 min, and deposited on Formvar-carbon coated EM grids for 15 min. Then, samples were washed with PBS 0,1 M, and post-fixed with 1% Glutaraldehyde for 5 min, washed with distilled water, and then contrasted in a mixture of uranyl acetate (1%) and methyl cellulose (0.5%). Samples were analyzed with a Jeol JEM1010 TEM, operating at 80 kV. Four different samples were analysed for each of the isolation methods, and 100 vesicles were counted in each sample. Images were recorded on a MegaView III digital camera, and EVs size was determined using the Olympus Image Analysis Software. The sample analysis was performed at the Microscopy facility of the Central Service for Experimental Research (SCSIE) from the University of Valencia.

## AlphaScreen™ Technology.

Five  $\mu\text{L}$  of EVs resuspended in PBS were transferred to a 96-well white 1/2 area microplate (Perkin Elmer, Madrid, Spain). Samples were incubated overnight at 4°C with 10  $\mu\text{L}$ /well of anti-human CD9 antibody (SHI-EXO-M01-50; CosmoBio Co, Tokyo, Japan) conjugated to AlphaLisa acceptor beads (10  $\mu\text{g}/\text{mL}$ ; 6772001, Perkin Elmer, Madrid, Spain), and 10  $\mu\text{L}$ /well of biotinylated human anti-CD63 antibody (3 nM, SHI-EXO-M02-50, CosmoBio Co, Tokyo, Japan) previously biotinylated. Then, 25  $\mu\text{L}$ /well of AlphaScreen™ streptavidin-coated donor beads (40  $\mu\text{g}/\text{mL}$ ; 6760002, Perkin Elmer, Madrid, Spain) were added and incubated in the dark for another 30 min at RT. A signal appears (excitation spectra at 680nm, emission spectra at 615nm) if the distance between both beads is less than 200nm (compatible with exosomes size and other small EVs) thanks to the reactivity of O<sub>2</sub>, and is detected using a Multifunctional microplate reader CLARIOstar® (BMG LABTECH, Ortenberg, Germany). Assays were carried out at Centro de Investigación Principe Felipe, Valencia, Spain.

## HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA).

Whole miRNA transcriptome expression analysis was performed with urine derived EVs of PCa patients and HDs using the HTG EdgeSeq System (HTG Molecular Diagnostics, Inc., Tucson, AZ, USA) with the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA). This assay quantified the expression of 2083 human RNA transcripts (<https://www.htgmolecular.com/assays/mirna-wta>).

The same amount of EVs ( $3,6 \times 10^9$ ) from each patient were digested with proteinase K following the manufacturer's instructions. miRNAs of interest were then selected by a protection nuclease assay (qNPA) in the HTG EdgeSeq processor using miRNA Whole Transcriptome Assay (miRNA WTA) panel (HTG Molecular Diagnostics, Inc., Tucson, AZ, USA). Library prepared with the miRNA selected was amplified by PCR using adapters for NextSeq 550 System sequencer (Illumina, San Diego, CA, USA).

Samples were purified using Agencourt AMPure XP beads kit (Beckman Coulter, Brea, CA, USA), and then quantified by ABI 7500 Fast Real-Time PCR System (qPCR) using KAPA Library Quant Kit Universal qPCR Mix (KAPA Biosystems, Wilmington, MA, USA). For the qPCR, six standards were used in triplicate. Negative controls for PCR and qPCR were also used. After library quantification, all samples were normalized to a concentration of 20 pM. Library sequencing was performed using Next Generation Sequencing (NGS) in a NextSeq 550 System, High Output, 75 cycle v2.5 (Illumina, San Diego, CA, USA). Sequenced data were processed in HTG Parser Software using Bowtie2 for sequenced reads alignment.

## Statistical analysis

Kruskal-Wallis non-parametric test and U- Mann Whitney test for post-hoc pairwise comparisons were used to perform a statistical analysis of the different characterization methods. All statistical inference was performed with two-tailed tests with a significance level of 5%.

Additionally, in the processing of HTG EdgeSeq data, Principal Component Analysis was used for data visualization and DESeq2 method for the study of differentially expressed miRNAs. The IBM SPSS Statistics V22.0 package (SPSS, Chicago, IL), R v. 4.0.1 and GraphPad Prism 7 (GraphPad Software Inc.) were used for statistical analysis [61].

## Results

### Spectrophotometric quantification and NTA

In order to compare protein and particle yields between the three EVs-isolation procedures, a spectrophotometric quantification at 280 nm, as well as the determination of particle concentration and size distribution by NTA, was performed. Absorbance measurements showed similar protein concentrations in UC ( $7.57 \pm 8.2 \mu\text{g/mL}$ ) and SEC ( $7.468 \pm 3.77 \mu\text{g/mL}$ ), but a significant increase was noted in Exolute® samples ( $25.99 \pm 19.25 \mu\text{g/mL}$ ) (Figure S1A). Figure S1B shows this amount of protein broken down into PCa patients and HDs, where no significant differences were found between the two groups in any of the three isolation methods.

NTA measurements revealed that UC would provide the highest number of particles per mL ( $4.13 \pm 3 \times 10^{11}$  particles/mL) in comparison with Exolute® ( $1.78 \pm 1.03 \times 10^{11}$  particles/mL)  $p$ -value = 0.021, and SEC ( $8.1 \pm 3.54 \times 10^{10}$  particles/mL)  $p$ -value = 0.0011 (Fig. 1A). On the other hand, NTA analyses revealed that, whereas Exolute® and UC particles had a similar size distribution (modes of  $167.84 \pm 32.19$  and  $160.28 \pm 18.51$  nm, respectively;  $p$ -value > 0.99), SEC particles showed larger size ( $194.1 \pm 16.4$  nm) ( $p$ -value = 0.0026) (Fig. 1B).

The ratio between the number of particles/mL and the  $\mu\text{g}$  of proteins/mL was next calculated, as an estimation of the purity of the sample, being the higher ratio for UC samples ( $5.97 \pm 6.24 \times 10^{10}$ ), followed by SEC ( $2.01 \pm 0.97 \times 10^{10}$ ) and Exolute® ( $0.44 \pm 0.28 \times 10^{10}$ ), respectively (Fig. 1C).

Taken together, these results show non-significant differences between PCa patients and HDs. Still, EVs isolated from UC and SEC showed a similar pattern, with higher particle and protein concentration in samples derived from PCa patients, which was inverted in Exolute®-EVs samples (Fig. 1D and Figure S1B).

## Characterization of isolated EVs by Transmission Electron Microscopy

To obtain an accurate determination of the size of the isolated EVs by the different isolation methods, and confirm previous data obtained by NTA, we next performed TEM analyses. Membrane-limited vesicles were easily detected by TEM (Fig. 2A). Interestingly, whereas UC and SEC-isolated EVs preparations showed a clear background in most preparations, the presence of a “dense background smudge” was noted in some Exolute® samples, consistent with the presence of protein aggregates, as it has been previously described by Karimi *et al* [25]. TEM analysis showed that EVs displayed similar sizes between the three isolation methods, with a median around 90 nm (means were ranged between 80.2–86.3; 84-91.5 and 78.7-105.7 for Exolute®, UC and SEC, respectively ( $p$ -value = 0.65)) (Fig. 2B). Differences in EVs size distribution were detected, where vesicles in the range of 60 to 90 nm of diameter represented the main isolated population (around 40% of total). Nevertheless, SEC-isolated EVs had a broader size distribution than those isolated with Exolute® and UC. In fact, Exolute® seemed to favour the isolation of medium size EVs (60–120 nm) in comparison with SEC and UC (Fig. 2C).

## Comparative marker analyses by AlphaScreen™ Technology

Human EVs commonly present tetraspanin proteins at their surface, such as CD63, CD81 and CD9 [22, 24], which have been also detected in EVs from urine [25]. An adaptation of the amplified luminescent proximity homogeneous assay (ALPHA) technology [26] was used to detect two of these tetraspanins, CD9 and CD63, in EVs smaller than 200 nm, isolated from Exolute®, UC and SEC. Firstly, data shows that CD9 and CD63 were highly enriched in EVs from almost all the samples (with the exception of sample ID 129, which provided very low signals) when compared to total urine (TUr), confirming that the three methods were useful to isolate CD9 and CD63 positive EVs, to a certain extent. As shown in Fig. 3A, SEC is the most efficient method to provide a reliable concentration of CD9 and CD63 positive EVs ( $9.7 \times 10^5 \pm 9.1 \times 10^5$ ), followed by UC ( $6.7 \times 10^5 \pm 8.9 \times 10^5$ ) and Exolute® ( $1.1 \times 10^5 \pm 1.3 \times 10^5$ ), respectively ( $p$ -value = 0.0233). Interestingly, when luminescent data are disaggregated per sample and isolation method (Fig. 3B) it can be observed that SEC provides sufficient signal in almost every sample, whereas there is a broad variability in CD9 and CD63 combined signals in UC-EVs. Thus, whereas UC-EVs had the higher mean signal in four samples, EVs isolated from the rest provided low signals (below 200,000), SEC-EVs showed the higher mean signal in 6 out of 10 patients, but only 2 patients provided signals below 200,000. On the other hand, no differences were detected between PCa and HDs (Figure S2).

## Evaluation of isolation by HTG EdgeSeq miRNA Whole Transcriptome Assay



A whole miRNA transcriptomic assay was performed on the isolated EVs using the WTA panel on an HTG EdgeSeq System (HTG Molecular Diagnostics). miRNA expression levels were quantified by NGS. Median of the sum of the normalized miRNA counts was higher in EVs isolated from SEC [16814 (range: 15650–17121)], followed by UC [16260 (range: 15796–16874)], and Exolute® [16137 (range: 15575–16710)] ( $p$ -value = 0.046) (Fig. 4).

Heatmap and PCA plots show that cases were not aggregated based on their miRNA expression profiles as would be expected, but they were classified more dependent of the EVs isolation method (Figure S3). Despite this, miRNA expression levels correlations in each case between the three EVs isolation methods were statistically significant (Table 2, Figures S4-S13). However, in global, the correlation was better between UC and SEC [Median R2 = 0.8 (range: 0.62–0.91)] than any of these methods with Exolute® (Table 2).

Table 2  
Coefficient correlation values (R2) between the three EVs-isolation procedures

Sample ID	Type of sample	UC-SEC	SEC- Exolute®	UC- Exolute®
127	PCa patient	0.77	0.66	0.73
129	PCa patient	0.65	0.64	0.70
132	PCa patient	0.82	0.57	0.67
144	PCa patient	0.84	0.77	0.75
146	PCa patient	0.91	0.76	0.75
148	PCa patient	0.72	0.79	0.71
161	HDs	0.62	0.67	0.77
163	HDs	0.78	0.81	0.69
164	HDs	0.83	0.63	0.64
167	HDs	0.82	0.63	0.69
Median (range)		0.8 (0.62–0.91)	0.67 (0.57–0.81)	0.71 (0.64–0.77)
Average (SD*)		0.78 (0.09)	0.69 (0.08)	0.71 (0.04)
*SD, standard deviation; HDs, healthy donors; PCa, prostate cancer				

The differential expression analysis (DEA) between PCa cases and HDs for each EVs isolation method showed that a total of 21 and 3 miRNAs were differentially expressed ( $p$ -adjusted < 0.1) between groups for SEC and UC, respectively. However, no miRNAs were discriminated in the case of Exolute®. Remarkably, only miR-8052 matched between the SEC and UC miRNA sets (Figure S14).

Interestingly, the evaluation of two sets of RNAs (housekeeping genes and *Let-7* miRNA family) from different EVs isolation methods showed significant differences between UC and SEC with Exolute®

(Fig. 5), suggesting that Exolute® method offers the lowest performance from the biological point of view.

Lastly, the overall miRNA expression was divided into different quartiles ( $q1 < q2 < q3 < q4$ ), and a correlation with the EVs isolation method used was performed, indicating that those miRNAs with lower expression levels would be compromised depending on the type of isolation method used, as can be subtracted from the R2 values of the different quartiles (Figure S15).

## Discussion

EVs have been postulated as a valuable source of potential biomarkers in PCa that at some point would complement or replace the routine diagnostic procedures [15, 27]. Urinary EVs take special relevance since their cargo reflect changes in the cellular biology of the tumour in a specific point of its progression and can be isolated without any invasive procedure. However, translation of these biomarkers into the clinical setting is not exempt of limitations, including the irreproducibility of results as one of the most important [28]. In this sense, EVs isolation and characterization approaches still constitute a scientific challenge [23]. Hence, with the aim of deepening in the knowledge of EVs isolation methods, we have evaluated three different methodologies including the classical UC and SEC, as well as a commercial kit (Exolute®). EVs characterization was performed using NTA, TEM, spectrophotometry (Nanodrop), AlphaScreen™ Technology and whole miRNA transcriptome expression analysis with the EdgeSeq System (HTG Molecular Diagnostics). For this purpose, a series of urines collected from 10 individuals (6 PCa patients and 4 HDs) were analysed with each isolation method.

Absorbance measurements showed similar protein concentrations in UC and SEC, however a significant increase was noticed in Exolute® samples (Figure S1A). This effect can be explained by TEM analysis, in which preparations from EVs obtained with Exolute® showed a background of precipitated proteins (Fig. 2A) consistent with the presence of protein aggregates, as it has been previously described [29]. NTA evaluation showed that UC provided the higher number of particles per mL and particles per  $\mu\text{g}$  protein ratio, in comparison with SEC and Exolute®, suggesting a higher EV yield obtained by this technique (Figs. 1A and 1C). Besides that, a significant increase in size of particles obtained by SEC was noticed ( $\sim 190$  nm), when compared to the other EVs isolation procedures ( $\sim 165$  nm) (Fig. 1B). However, no differences in size were appreciated when EVs were analysed by TEM with a median in size of around 90 nm (range: 30–200 nm). Interestingly, approximately 95% of EVs were ranged from 30–120 nm, and around 40% were between 60–90 nm of diameter (Fig. 2C). These findings correlate with previous reports showing that the size of urine EVs varies from 30 to 100 nm [30–33]. Discordances between NTA and TEM herein reported may be due to different aspects including: the difficulty of NTA to resolve EVs aggregates (a correct dilution of the sample is crucial to avoid this) [34]; the limitation of NTA in detecting particles which diameter is lower than 100 nm [35] and finally, to the size overestimation of NTA [36, 37]. Additionally, and as mentioned above, TEM analyses revealed high variability in EVs yield obtained by Exolute®, with some samples showing the presence of protein aggregates that would explain the highest protein content of the spectrophotometric analysis (Fig. 2A). Interestingly, SEC-isolated EVs had a broader

size distribution than those isolated with Exolute® and UC, which could be due to the growing evidences that SEC minimally alters the physical properties of EVs, whereas UC might cause vesicle rupture or fusion with proteins because of the high speed used in centrifugations [38]. As a whole, no significant differences in particle concentration and size (measured by both NTA or TEM) were detected between PCa samples and HDs (Fig. 1D) which is in accordance with previous studies [30].

Once characterized through NTA and TEM, EVs were analysed with AlphaScreen™ Technology, a strategy lately used to improve the typical immunoassays [39] through the simultaneous detection for two specific EV-tetraspanins, CD9 and CD63[22, 24] and designed to specifically detect EVs lower than 200 nm. Our AlphaScreen data revealed that all three isolation methods obtained CD9 and CD63 positive EVs, as can be appreciated in Fig. 3A where luminescent signal was higher in purified EVs compared to crude urine. Furthermore, SEC provided the highest luminescent intensity followed by UC and Exolute®, which luminescent intensity was significantly lower. Interestingly, a high signal variation was noted among the analysed cases, especially in Exolute® and UC isolated EVs, for which in some cases the luminescent signal was low or null, whereas SEC isolated EVs provided a measurable signal in most of the cases (Fig. 3B). These differences would be related to those herein noticed with regards EVs size distribution, or as suggested by some reports, as consequence of differences in the membrane proteomic content of small and large EVs [40]. Moreover, EVs rupture due to UC high-speed centrifugations[38] or the reported variability on EVs yield depending on the equipment and operator technical variability could have affected the results [41]. Hence, and according to the AlphaScreen™ Technology, our results highlight SEC as the most efficient method to isolate CD9 and CD63 positive microvesicles, followed by UC and Exolute®, respectively. Similar to the other characterization methods, no differences of luminescent signal were appreciated between EVs isolated from PCa patients and HDs for any of the isolation methods tested.

Forward characterization of EVs was carried through a whole miRNA transcriptomic analysis by using one of the newest and most reproducible RNA quantification platforms using the EdgeSeq Technology (HTG Molecular Diagnostics), currently used in many studies [42, 43]. Among the advantages of this system are that it does not require an RNA-extraction step which, reduces the extraction-associated data bias and sample loss; and the low input of sample necessary for being analysed [44]. Our results have shown that the sum of the normalized miRNA counts was higher in EVs isolated from SEC, followed by UC and Exolute® (Fig. 4), suggesting that the isolation methods influence on the yield of the transcriptomic analysis. Many -omic studies have been found to be highly dependent on the EVs isolation procedures, so that different methods produce EVs and EV sub-fractions of variable homogeneity, which makes difficult to extrapolate findings between different studies of EVs [7]. This is in line with the results we have obtained, in which samples were classified based more on the EVs isolation method than on their origin (PCa patients or HDs) (Figure S3). Despite this, correlation of miRNA profiles between the different isolation approaches was high in all cases, being better between UC and SEC (Table 2). Interestingly, when miRNA expression was divided into quartiles, the best correlation coefficients ( $R^2$ ) were obtained in q4 (higher number of miRNAs) with a  $R^2 = 0.97$  between SEC and UC, the correlation in

q2 and q1 being lower (Figure S15). In order to demonstrate that the isolation procedures influence at biological level, two sets of RNA were evaluated: the housekeeping genes provided by the assay and the *Let-7* family of miRNAs. This approach showed significant differences with regards number of reads for any of the two RNA sets of UC and SEC with Exolute® (Fig. 5), indicating that Exolute® provides the lowest performance from the biological point of view.

DEA between PCa cases and HDs for each EVs isolation method showed that a total of 21 and 3 miRNAs were differentially expressed between groups for SEC and UC respectively, and none for Exolute®. The only miRNA that was differentially expressed in both methods was miR-8052 [45], a miRNA not previously described in PCa but in serum from sepsis patients with different outcomes [46]. Remarkably, two of the 3 miRNAs differentially expressed in EVs isolated by UC from urine of PCa patients were miR-142-5p and miR-223-3p, two miRNA that have been recently described in EVs from urine isolated also by UC as non-invasive PCa diagnostic biomarkers [47].

As a whole, our results point to what other authors have suggested, the need of methodological standardization of EVs isolation and characterization in order to guaranty the success and reproducibility of the subsequent analysis, especially for clinical settings, where a large number of samples should be analysed [48–50]. In this line, we suggest developing a codification system focused on the EV isolation and characterization variables similar to the SPREC codification system for pre-analytical conditions [51] that we have introduced with our samples (Table 1) and that provides information on the handling of biological specimens before analysis, another critical point that not always comprehensively considered [52, 53].

## Conclusion

As a whole, our results show that UC and SEC, the most widespread EVs isolation methods in research laboratories, provided better results in terms of EVs yield and purity than Exolute®, with no significant differences in terms of EV-size. Interestingly, luminescent AlphaScreen assay demonstrated a significant enrichment of CD9 and CD63 positive microvesicles in SEC and UC methods compared with Exolute®. The effect of this EVs heterogeneity is translated at miRNA profiles, which were dependent on the type of the isolation method used, although the highest correlation at RNA level was observed between UC and SEC, especially for those miRNAs with higher expression. Definitively, our study highlights the importance of standardizing the urine EV isolation methods to guaranty the analytical reproducibility necessary for their implementation in a clinical setting.

## Declarations

## Ethics approval and consent to participate

Written informed consent for sample donation for research purposes was obtained from all patients prior to sample collection, and the study was approved by the Clinical Research Ethics Committee (CREC) and

the Institutional Ethics Committee (Ref. PROMETEO 2016/103), at the meeting held on May 28, 2015. All methods used during the study were performed in accordance with the relevant guidelines and regulations.

## **Consent for publication**

All authors have read and approved the manuscript.

## **Availability of data and materials**

Data and materials available upon request.

## **Competing interests**

The authors declare no conflict of interest.

## **Acknowledgements and funding**

This work was supported by grants PROMETEO 2016/103; PROMETEO 2016/156 and PROMETEO 2020/071 from the Conselleria de Educació, Cultura y Deporte of Generalitat Valenciana and PID2019-105713GB-I00, Agencia Estatal de Investigación, Spain. The research group is part of “Red Traslacional para la Aplicación Clínica de Vesículas Extracelulares” (RED2018-102411-T), Agencia Estatal de Investigación, Spain.

Authors thank Patricia Carretero Hinojosa and Tania Mazcuñán Vitiello for technical assistance. We also thank the Biobank of the Fundación Instituto Valenciano de Oncología for providing the biological samples for the analysis.

All authors have read the journal's policy on disclosure of potential conflicts of interest and declare no conflict of interest.

## **Authors' contributions**

García-Flores M.: Methodology, formal analysis, investigation, data curation, writing-original draft preparation, visualization. Sánchez-López C.: Methodology, software, formal analysis, investigation, data curation, writing-original draft preparation, visualization. Ramírez-Calvo M.: Methodology, formal analysis, investigation, data curation. Fernández-Serra A.: Software, investigation, data curation, visualization. Marcilla A.: Conceptualization, investigation, resources, writing—review and editing, supervision, funding acquisition. López-Guerrero JA.: Conceptualization, investigation, resources, writing—review and editing,

supervision, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.

## References

1. Bunting, P.S. Screening for Prostate Cancer with Prostate-Specific Antigen: Beware the Biases. *Clin Chim Acta* 2002, *315*, 71–97.
2. Freedland, S.J.; Partin, A.W. Prostate-Specific Antigen: Update 2006. *Urology* 2006, *67*, 458–460.
3. Thompson, I.M.; Ankerst, D.P.; Chi, C.; Lucia, M.S.; Goodman, P.J.; Crowley, J.J.; Parnes, H.L.; Coltman, C.A. Operating Characteristics of Prostate-Specific Antigen in Men with an Initial PSA Level of 3.0 Ng/ml Or Lower. *JAMA* 2005, *294*, 66–70.
4. Thurtle, D.R.; Greenberg, D.C.; Lee, L.S.; Huang, H.H.; Pharoah, P.D.; Gnanapragasam, V.J. Individual Prognosis at Diagnosis in Nonmetastatic Prostate Cancer: Development and External Validation of the PREDICT Prostate Multivariable Model. *PLoS Med.* 2019, *16*, e1002758.
5. Filella, X.; Foj, L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. *Int J Mol Sci* 2016, *17*, 1784.
6. Lawson, C.; Vicencio, J.M.; Yellon, D.M.; Davidson, S.M. Microvesicles and Exosomes: New Players in Metabolic and Cardiovascular Disease. *J Endocrinol* 2016, *228*, R57-R71.
7. Yáñez-mó, M.; Siljander, P.R.; Andreu, Z.; Bedina, A.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J. *et al.* Biological Properties of Extracellular Vesicles and their Physiological Functions. *J Extracell Vesicles* 2015, *4*, 27066.
8. Andreu, Z.; Rivas, E.; Sanguino-pascual, A.; Lamana, A.; Marazuela, M.; González-Alvaro, I.; Sánchez-Madrid, F.; de la Fuente, H.; Yáñez-Mó, M. Comparative Analysis of EV Isolation Procedures for miRNAs Detection in Serum Samples. *J Extracell Vesicles* 2016, *5*, 31655.
9. Nilsson, R.J.A.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X.O.; Widmark, A. Prostate Cancer-Derived Urine Exosomes: A Novel Approach to Biomarkers for Prostate Cancer. *Br J Cancer* 2009, *100*, 1603–1607.
10. Emanuelli, C.; Shearn, A.I.U.; Angelini, G.D.; Sahoo, S. Exosomes and Exosomal miRNAs in Cardiovascular Protection and Repair. *Vascul Pharmacol* 2015, *71*, 24–3.
11. Pol, E.V.D.; Böing, A.N.; Harrison, P.; Sturk, A.; Nieuwland, R. Classification, Functions, and Clinical Relevance of Extracellular Vesicles. *Pharmacol Rev* 2012, *64*, 676–705.
12. Vader, P.; O. Breakefield, X.; J.A. Wood, M. Extracellular Vesicles: Emerging Targets for Cancer Therapy. *Trends Mol Med* 2015, *20*, 385–393.
13. Patel, G.K.; Khan, M.A.; Bhardwaj, A.; Srivastava, S.K.; Zubair, H.; Patton, M.C.; Singh, S.; Khushman, M.; Singh, A.P. Exosomes Confer Chemoresistance to Pancreatic Cancer Cells by Promoting ROS Detoxification and miR-155-Mediated Suppression of Key Gemcitabine-Metabolising Enzyme, DCK. *Br J Cancer* 2017, *116*, 609–619.
14. Kalluri, R. The Biology and Function of Exosomes in Cancer. *J Clin Investig* 2016, *126*, 1208–1215.

15. Tai, Y.; Lin, C.; Li, T.; Shen, T.; Hsieh, J.; Chen, B.P.C. The Role of Extracellular Vesicles in Prostate Cancer with Clinical Applications. *Endocr Relat Cancer* 2020, *27*, R133-R144.
16. Vlaeminck-Guillem, V. Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management. *Front Oncol* 2018, *8*, 222.
17. Greening, D.W.; Xu, R.; Ji, H.; Tauro, B.J.; Simpson, R.J. A Protocol for Exosome Isolation and Characterization: Evaluation of Ultracentrifugation, Density-Gradient Separation, and Immunoaffinity Capture Methods. *Methods Mol Biol* 2015, *1295*, 179–209.
18. Gould, S.J.; Raposo, G. As we Wait: Coping with an Imperfect Nomenclature for Extracellular Vesicles. *J Extracell Vesicles* 2013, *2*, 10.
19. Helwa, I.; Cai, J.; Drewry, M.D.; Zimmerman, A.; Dinkins, B.; Khaled, M.L.; Seremwe, M.; Dismuke, W.M.; Bieberich, E.; Stamer, W.D. *et al.* A Comparative Study of Serum Exosome Isolation using Differential Ultracentrifugation and Three Commercial Reagents. *PLoS ONE* 2017, 1–22.
20. Lee, J.; Kwon, M.H.; Kim, J.A.; Rhee, W.J. Detection of Exosome miRNAs using Molecular Beacons for Diagnosing Prostate Cancer. *Artif Cells Nanomed Biotechnol* 2018, *46(sup3)*, S52-S63.
21. Royo, F.; Zun, P.; Egia, A.; Perez, A.; Loizaga, A.; Arceo, R.; Lacasa, I.; Rabade, A.; Arrieta, E.; Bilbao, R. *et al.* Different EV Enrichment Methods Suitable for Clinical Settings Yield Different Subpopulations of Urinary Extracellular Vesicles from Human Samples. *J Extracell Vesicles* 2016, *1*, 1–11.
22. Lötval, J.; Hill, A.F.; Hochberg, F.; Buzás, E.I.; Di, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Quesenberry, P.; Sahoo, S. *et al.* Minimal Experimental Requirements for Definition of Extracellular Vesicles and their Functions: A Position Statement from the International Society for Extracellular Vesicles. *J Extracell Vesicles* 2014, *3*, 26913.
23. Szatanek, R.; Baran, J.; Siedlar, M.; Baj-krzyworzeka, M. Isolation of Extracellular Vesicles: Determining the Correct Approach (Review). *Int J Mol Med*, 2015, *36*, 11–17.
24. Mathivanan, S.; Ji, H.; Simpson, R.J. Exosomes: Extracellular Organelles Important in Intercellular Communication. *J Proteom* 2010, *73*, 1907–1920.
25. Campos-Silva, C.; Suarez, H.; Jara-Acevedo, R.; Linares-Espinos, E.; Martinez-Pineiro, L.; Yanez-Mo, M.; Vales-Gomez, M. High Sensitivity Detection of Extracellular Vesicles Immune-Captured from Urine by Conventional Flow Cytometry. *Sci Rep*, 2019, *9*, 2042–8.
26. Yoshioka, Y.; Kosaka, N.; Konishi, Y.; Ohta, H.; Okamoto, H.; Sonoda, H.; Nonaka, R.; Yamamoto, H.; Ishii, H.; Mori, M. *et al.* Ultra-Sensitive Liquid Biopsy of Circulating Extracellular Vesicles using ExoScreen. *Nat Commun*, 2014, *5*, 3591.
27. Braun, F.; Müller, R. Urinary Extracellular Vesicles as a Source of Biomarkers Reflecting Renal Cellular Biology in Human Disease. *Methods Cell Biol*, 2019, *154*, 43–65.
28. Scherer, A. Reproducibility in Biomarker Research and Clinical Development: A Global Challenge. *Biomark Med*, 2017, *11*, 309–312.
29. Karimi, N.; Cvjetkovic, A.; Jang, S.C.; Crescitelli, R.; Hosseinpour Feizi, M.A.; Nieuwland, R.; Lötval, J.; Lässer, C. Detailed Analysis of the Plasma Extracellular Vesicle Proteome After Separation from Lipoproteins. *Cell Mol Life Sci*, 2018, *75*, 2873–2886.

30. Bryzgunova, O.E.; Zaripov, M.M.; Skvortsova, T.E.; Lekchnov, E.A.; Grigor'eva, A.E.; Zaporozhchenko, I.A.; Morozkin, E.S.; Ryabchikova, E.I.; Yurchenko, Y.B.; Voitsitskiy, V.E. *et al.* Comparative Study of Extracellular Vesicles from the Urine of Healthy Individuals and Prostate Cancer Patients. *PLoS ONE*, 2016, *11*, e0157566.
31. Fang, D.Y.; King, H.W.; Li, J.Y.; Gleadle, J.M. Exosomes and the Kidney: Blaming the Messenger. *Nephrology (Carlton)*, 2013, *18*, 1–10.
32. Murakami, T.; Oakes, M.; Ogura, M.; Tovar, V.; Yamamoto, C.; Mitsuhashi, M. Development of Glomerulus-, Tubule-, and Collecting Duct-Specific mRNA Assay in Human Urinary Exosomes and Microvesicles. *PLoS ONE*, 2014, *9*, e109074.
33. Singhto, N.; Vinaiphath, A.; Thongboonkerd, V. Discrimination of Urinary Exosomes from Microvesicles by Lipidomics using Thin Layer Liquid Chromatography (TLC) Coupled with MALDI-TOF Mass Spectrometry. *Sci Rep*, 2019, *9*, 13834–11.
34. Lozano-Ramos, I.; Bancu, I.; Oliveira-Tercero, A.; Armengol, M.P.; Menezes-Neto, A.; Portillo, H.A.D.; Lauzurica-Valdemoros, R.; Borràs, F.E. Size-Exclusion Chromatography-Based Enrichment of Extracellular Vesicles from Urine Samples. *J Extracell Vesicles*, 2015, *4*, 27369.
35. Van der Pol, E.; Coumans, F.A.W.; Grootemaat, A.E.; Gardiner, C.; Sargent, I.L.; Harrison, P.; Sturk, A.; van Leeuwen, T.G.; Nieuwland, R. Particle Size Distribution of Exosomes and Microvesicles Determined by Transmission Electron Microscopy, Flow Cytometry, Nanoparticle Tracking Analysis, and Resistive Pulse Sensing. *J Thromb Haemost*, 2014, *12*, 1182–1192.
36. Bachurski, D.; Schuldner, M.; Nguyen, P.; Malz, A.; Reiners, K.S.; Grenzi, P.C.; Babatz, F.; Schauss, A.C.; Hansen, H.P.; Hallek, M. *et al.* Extracellular Vesicle Measurements with Nanoparticle Tracking Analysis – an Accuracy and Repeatability Comparison between NanoSight NS300 and ZetaView. *J Extracell Vesicles*, 2019, *8*, 1596016.
37. Serrano-Pertierra, E.; Oliveira-Rodríguez, M.; Matos, M.; Gutiérrez, G.; Moyano, A.; Salvador, M.; Rivas, M.; Blanco-López, M.C. Extracellular Vesicles: Current Analytical Techniques for Detection and Quantification. *Biomolecules (Basel, Switzerland)*, 2020, *10*, 824.
38. Monguió-Tortajada, M.; Gálvez-Montón, C.; Bayes-Genis, A.; Roura, S.; Borràs, F.E. Extracellular Vesicle Isolation Methods: Rising Impact of Size-Exclusion Chromatography. *Cell Mol Life Sci*, 2019, *76*, 2369–2382.
39. Yoshioka, Y.; Kosaka, N.; Konishi, Y.; Ohta, H.; Okamoto, H.; Sonoda, H.; Nonaka, R.; Yamamoto, H.; Ishii, H.; Mori, M. *et al.* Ultra-Sensitive Liquid Biopsy of Circulating Extracellular Vesicles using ExoScreen. *Nat Commun*, 2014, *5*, 3591.
40. Mariscal, J.; Vagner, T.; Kim, M.; Zhou, B.; Chin, A.; Zandian, M.; Freeman, M.R.; You, S.; Zijlstra, A.; Yang, W. *et al.* Comprehensive Palmitoyl-Proteomic Analysis Identifies Distinct Protein Signatures for Large and Small Cancer-Derived Extracellular Vesicles. *J Extracell Vesicles*, 2020, *9*, 1764192.
41. Torres Crigna, A.; Fricke, F.; Nitschke, K.; Worst, T.; Erb, U.; Karremann, M.; Buschmann, D.; Elvers-Hornung, S.; Tucher, C.; Schiller, M. *et al.* Inter-Laboratory Comparison of Extracellular Vesicle Isolation Based on Ultracentrifugation. *Transfus Med Hemother*, 2020, 1–12.



42. Bustos, M.A.; Tran, K.D.; Rahimzadeh, N.; Gross, R.; Lin, S.Y.; Shoji, Y.; Murakami, T.; Boley, C.L.; Tran, L.T.; Cole, H. *et al.* Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis. *Cancers* 2020, *12*, 1692.
43. Nziza, N.; Jeziorski, E.; Delpont, M.; Cren, M.; Chevassus, H.; Carbasse, A.; Mahe, P.; Abassi, H.; Joly-Monrigal, P.; Schordan, E. *et al.* Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis. *Cells (Basel)*, 2019, *8*, 1521.
44. Godoy, P.M.; Barczak, A.J.; DeHoff, P.; Srinivasan, S.; Etheridge, A.; Galas, D.; Das, S.; Erle, D.J.; Laurent, L.C. Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms. *Cell Reports* 2019, *29*, 4212–4222.e5.
45. Griffiths-Jones, S. miRBase: microRNA Sequences, Targets and Gene Nomenclature. *Nucleic Acids Res* 2006, *34*, D140-D144.
46. Wang, H.; Zhang, P.; Chen, W.; Jie, D.; Dan, F.; Jia, Y.; Xie, L. Characterization and Identification of Novel Serum MicroRNAs in Sepsis Patients with Different Outcomes. *Shock*, 2013, *39*, 480–487.
47. Barceló, M.; Castells, M.; Bassas, L.; Vigués, F.; Larriba, S. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis. *Sci Rep*, 2019, *9*, 13772–16.
48. Gurunathan, S.; Kang, M.; Jeyaraj, M.; Qasim, M.; Kim, J. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. *Cells*, 2019, *8*, 307.
49. Ma, C.; Jiang, F.; Ma, Y.; Wang, J.; Li, H.; Zhang, J. Isolation and Detection Technologies of Extracellular Vesicles and Application on Cancer Diagnostic. *Nanotechnology and Microtechnology in drug delivery Systems* 2019, *17*, 155932581989100–1559325819891004.
50. Xu, R.; Greening, D.W.; Zhu, H.; Takahashi, N.; Simpson, R.J. Extracellular Vesicle Isolation and Characterization: Toward Clinical Application. *J Clin Invest*, 2016, *126*, 1152–1162.
51. Betsou, F.; Bilbao, R.; Case, J.; Chuaqui, R.; Clements, J.A.; De Souza, Y.; De Wilde, A.; Geiger, J.; Grizzle, W.; Guadagni, F. *et al.* Standard PREanalytical Code Version 3.0. *Biopreserv Biobank*, 2018, *16*, 9–12.
52. Carraro, P.; Zago, T.; Plebani, M. Exploring the Initial Steps of the Testing Process: Frequency and Nature of Pre-Preanalytic Errors. *Clin Chem*, 2012, *58*, 638–642.
53. Moore, H.M.; Compton, C.C.; Lim, M.D.; Vaught, J.; Christiansen, K.N.; Alper, J. 2009 Biospecimen Research Network Symposium: Advancing Cancer Research through Biospecimen Science. *Cancer Research* 2009, *69*, 6770–6772.
54. Zhou, H.; Yuen, P.S.T.; Pisitkun, T.; Gonzales, P.A.; Yasuda, H.; Dear, J.W.; Gross, P.; Knepper, M.A.; Star, R.A. Collection, Storage, Preservation, and Normalization of Human Urinary Exosomes for Biomarker Discovery. *Kidney International*, 2006, *69*, 1471–1476.
55. Betsou, F.; Lehmann, S.; Ashton, G.; Barnes, M.; Benson, E.E.; Coppola, D.; DeSouza, Y.; Eliason, J.; Glazer, B.; Guadagni, F. *et al.* Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code. *Cancer Epidemiol Biomarkers Prev*, 2010, *19*, 1004–1011.
56. Lehmann, S.; Guadagni, F.; Moore, H.; Ashton, G.; Barnes, M.; Benson, E.; Clements, J.; Koppandi, I.; Coppola, D.; Demiroglu, S.Y. *et al.* Standard Preanalytical Coding for Biospecimens: Review and Implementation of the Sample PREanalytical Code (SPREC). *Biopreserv Biobank*, 2012, *10*, 366–374.

57. Kosanovic, M.; Jankovi, M. Isolation of Urinary Extracellular Vesicles from Tamm- Horsfall Protein- Depleted Urine and their Application in the Development of a Lectin-Exosome-Binding Assay. *BioTechniques*, 2014, 57, 143–149.
58. Betsou, F.; Bilbao, R.; Case, J.; Chuaqui, R.; Clements, J.A.; De Souza, Y.; De Wilde, A.; Geiger, J.; Grizzle, W.; Guadagni, F. *et al.* Standard PREanalytical Code Version 3.0. *Biopreserv Biobank* 2018, 16, 9–12.
59. Böing, A.N.; van der Pol, E.; Grootemaat, A.E.; Coumans, F.A.W.; Sturk, A.; Nieuwland, R. Single-Step Isolation of Extracellular Vesicles by Size-Exclusion Chromatography. *J Extracell Vesicles* 2014, 3, 23430–11.
60. Théry, C.; Clayton, A.; Amigorena, S.; Raposo, G., Eds. *Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids.*; Wiley-Blackwell: United States, 2006; pp. 3.22.1–3.22.29.
61. Love, M.I.; Huber, W.; Anders, S. Moderated Estimation of Fold Change Anddispersion for RNA-Seq Data with DESeq2. *Genome Biol*, 2014, 15, 550.